期刊文献+

组织因子途径抑制物及前降钙素在新生儿败血症诊断中的价值 被引量:3

Significance of tissue factor pathway inhibitor and procalcitonin in diagnosis of neonatal septicemia
原文传递
导出
摘要 目的了解组织因子途径抑制物(TFPI)、前降钙素(PCT)在新生儿败血症诊断中的价值。方法通过检测48例败血症新生儿及30例健康新生儿血TFPI、PCT、C-反应蛋白(CRP)浓度,比较各炎症指标对诊断败血症的灵敏度、特异度、阳性预测值、阴性预测值和约登指数,评价它们对该病的早期诊断价值。结果(1)以TFPI≥30μg/L、CRP≥8mg/L、PCT〉12ng/ml为阳性标准,三指标对诊断败血症的灵敏度分别为86.92%、89.83%、87.50%,差异无显著性(P〉0.05),其中PCT的特异度96.67%、阳性预测值97.50%、阴性预测值83.32%、约登指数0.84;(2)在败血症组中,20例血培养阳性患儿的TFPI值为(35.5±4.5)μg/L,28例血培养阴性患儿的耵甲I值为(34.3±3.2)μg/L,差异无显著性(P〉0.05);但是相对于正常对照组(26.9±5.24)μg/L,败血症组的TFPI值明显升高(P〈0.05)。结论TFPI≥30μg/L对诊断新生儿败血症是一个具有较高灵敏度(86.92%)、中度特异度(59.3%)的指标;TFPI对新生儿败血症早期诊断有一定的价值,但均不及PCT及CRP,所有检测指标中PCT特异度、阳性预测值、阴性预测值、约登指数均最高。 Objective Neonatal septicemia is a critical disease in neonatal period. The early signs of septicemia in the newborn are generally nonspecific. Blood culture and the other clinical diagnostic measures are not sufficiently sensitive. The present study aimed at evaluating potential use of tissue factor pathway inhibitor ( TFPI ), procalcitonin (PCT) and C-reactive protein ( CRP ) in diagnosis of neonatal septicemia. Methods Fourty-eight newborn infants with septicemia enrolled the study. Twenty of the 48 cases had positive blood culture. The control group included 30 healthy newborns. Fasting blood samples were taken for bacterial cultures and TFPI、CRP、PCT determination. The sensitivity,specificity,positive and negative predictive values,Youden's index for TFPI,PCT and CRP were calculated. These values were compared with each other. Results ( 1 ) There were significant differences among the three groups in the contents of TFPI, CRP and PCT ( P 〈 0. 05 ). These markers were considered positive if TFPI ≥ 30 μg/L , CRP ≥ 8 mg/L, PCT ≥ 2ng/ml. Among these indices, PCT had the highest specificity (96. 67%), positive predictive value (97. 50% ),negative predictive value (83.32%), and Youden's index (0. 84). (2) In the whole group of newborns with septicemia,the TFPI was (35.5 ±4. 5) μg/L in the 20 newborns who had positive blood culture, and the TFPI was ( 34. 3 ± 3.2 ) μg/L in those who had negative blood culture. There was no significant difference between them ( P 〉 0. 05 ), but comparing with the normal control group ( 26. 9 ± 5.24 ) μg/L, the TFPI level in newborns with septicemia was significantly increased. Conclusion The level of TFPI is related with neonatal septicemia. TFPI concentration( TFPI ≥30 μg/L) may be used as a diagnostic tool with high sensitivity(86. 92% ) and moderate specificity(59. 3% ) in neonates suspected of infection. Among these indices ,PCT has the highest specificity ,positive predictive ,negative predictive values and Youden's index.
出处 《中国小儿急救医学》 CAS 2009年第2期125-127,130,共4页 Chinese Pediatric Emergency Medicine
关键词 婴儿 新生 败血症 组织因子途径抑制物 前降钙素 C-反应蛋白 Infant, newborn Septicemia Tissue factor pathway inhibitor Procalcitionin C-reactive protein
  • 相关文献

参考文献9

二级参考文献39

  • 1吴苔,陈莉亚.血清C反应蛋白在新生儿感染时的变化[J].浙江预防医学,2001,13(1). 被引量:19
  • 2陈大庆.新生儿败血症辅助检查评价[J].实用儿科临床杂志,2005,20(2):102-105. 被引量:58
  • 3毕玫荣,张岩.新生儿凝血特点及其影响因素[J].国外医学(妇幼保健分册),2005,16(1):15-17. 被引量:48
  • 4李贵霞,马莉,张丽霞.新生儿败血症降钙素原和C反应蛋白检测及临床意义[J].检验医学,2005,20(3):250-252. 被引量:33
  • 5吴仕孝.新生儿败血症诊断标准修订方案[J].中华儿科杂志,1988,26:163-164.
  • 6[4]ELISDBETH,ANNIE P.Vitamin K in neonates[J].Paediatric Drugs,2001,3(1):1-8.
  • 7[5]CHAN JC.Gene targeting in hemostasis.tisue factor pathway inhibitor[J].Front Biosci,2001,6:D 216-221.
  • 8Mousa SA, Bozarth J, Barrett JS. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. J Clin Pharmacol, 2003,43(7):727-734.
  • 9Moatti D,Haidar B,Fumeron F,et al. A new T-287C polymorphism in the 5' regulatory region of the tissue factor pathway inhibitor gene. Association study of the T-287C and C-399T polymorphisms with coronary artery disease and plasma TFPI levels. Thromb Haem
  • 10Abraham E,Reinhart K,Svoboda P,et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med, 2001,29(11):20

共引文献1068

同被引文献53

引证文献3

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部